Form 4: Adaptive Bio COO Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies Corp's President and COO, Julie Rubinstein, executed planned sales of common stock following option exercises in late March 2026.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), engaged in a series of stock option exercises and subsequent sales of common stock between March 27 and March 31, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 18, 2025.
• On March 27, 2026, Rubinstein acquired 14,722 shares by exercising stock options at $7.27 per share and sold a total of 19,060 shares at weighted average prices of $12.49 and $13.48.
• On March 30, 2026, she acquired another 14,722 shares by exercising options at $7.27 per share and sold 19,060 shares at a weighted average price of $12.63.
• On March 31, 2026, she acquired a further 14,722 shares by exercising options at $7.27 per share and sold 19,060 shares at a weighted average price of $13.45.
• Following these transactions, Rubinstein's direct beneficial ownership of common stock decreased by 27,736 shares to 455,878 shares, and her derivative securities (stock options) decreased to 111,163.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the transactions were pre-planned under a Rule 10b5-1 plan, which reduces the negative signaling typically associated with insider sales.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not reactive sale.
• Rubinstein exercised options at a significantly lower price ($7.27) than the sale prices (ranging from $12.07 to $13.87), indicating a profitable transaction for the insider.

Negatives

• The President and COO reduced her direct beneficial ownership of common stock by a net of 27,736 shares over the reported period.
• Insider selling, even if planned, can sometimes be interpreted by the market as a lack of confidence in the company's near-term growth prospects, although this is mitigated by the 10b5-1 plan.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals regarding management's perception of future company performance. While sales under a Rule 10b5-1 plan are pre-scheduled and mitigate concerns about opportunistic timing, a consistent pattern of insider selling across the industry could indicate broader concerns about valuation or market conditions.

Stakeholder Impact

• Shareholders: May view the reduction in direct beneficial ownership by a key executive with slight caution, though the 10b5-1 plan mitigates immediate concerns.

Key Dates

Recommendation

While the insider selling by the President and COO could be a minor negative signal, the fact that these transactions were executed under a pre-established Rule 10b5-1 trading plan significantly mitigates concerns about opportunistic selling. The profitable exercise of options also indicates a positive outcome for the executive. Without additional information on company performance or strategic shifts, the filing alone suggests a 'hold' recommendation, as it represents a routine, planned insider transaction rather than a strong directional signal.

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Julie Rubinstein, Officer Transaction, Biotechnology